135 related articles for article (PubMed ID: 12691129)
1. Utility of FDG-PET in differential diagnosis of benign and malignant fractures in acute to subacute phase.
Kato K; Aoki J; Endo K
Ann Nucl Med; 2003 Feb; 17(1):41-6. PubMed ID: 12691129
[TBL] [Abstract][Full Text] [Related]
2. Differentiation between malignant and benign pathologic fractures with F-18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography.
Shin DS; Shon OJ; Byun SJ; Choi JH; Chun KA; Cho IH
Skeletal Radiol; 2008 May; 37(5):415-21. PubMed ID: 18309481
[TBL] [Abstract][Full Text] [Related]
3. F-18 FDG positron emission tomography and benign fractures.
Shon IH; Fogelman I
Clin Nucl Med; 2003 Mar; 28(3):171-5. PubMed ID: 12592121
[TBL] [Abstract][Full Text] [Related]
4. Role of ¹⁸F-FDG PET/CT in differentiation of a benign lesion and metastasis on the ribs of cancer patients.
Choi HS; Yoo IeR; Park HL; Choi EK; Kim SH; Lee WH
Clin Imaging; 2014; 38(2):109-14. PubMed ID: 24361174
[TBL] [Abstract][Full Text] [Related]
5. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Ishijima H; Oya N; Sato N; Inoue T; Endo K
Radiology; 2001 Jun; 219(3):774-7. PubMed ID: 11376267
[TBL] [Abstract][Full Text] [Related]
6. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
7. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
[TBL] [Abstract][Full Text] [Related]
8. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
[TBL] [Abstract][Full Text] [Related]
9. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose.
Dehdashti F; Siegel BA; Griffeth LK; Fusselman MJ; Trask DD; McGuire AH; McGuire DJ
Radiology; 1996 Jul; 200(1):243-7. PubMed ID: 8657920
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.
Ulaner GA; Zindman AM; Zheng J; Kim TW; Healey JH
Clin Nucl Med; 2017 Apr; 42(4):264-270. PubMed ID: 28166159
[TBL] [Abstract][Full Text] [Related]
11. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis.
Wu H; Dimitrakopoulou-Strauss A; Heichel TO; Lehner B; Bernd L; Ewerbeck V; Burger C; Strauss LG
Eur J Nucl Med; 2001 Jun; 28(6):704-10. PubMed ID: 11440030
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 11C-choline PET and FDG PET for the differential diagnosis of malignant tumors.
Tian M; Zhang H; Oriuchi N; Higuchi T; Endo K
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1064-72. PubMed ID: 15014903
[TBL] [Abstract][Full Text] [Related]
13. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic usefulness of FDG PET for pancreatic mass lesions.
Koyama K; Okamura T; Kawabe J; Nakata B; Chung KH; Ochi H; Yamada R
Ann Nucl Med; 2001 Jun; 15(3):217-24. PubMed ID: 11545191
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.
Aoki J; Watanabe H; Shinozaki T; Takagishi K; Tokunaga M; Koyama Y; Sato N; Endo K
Skeletal Radiol; 2003 Mar; 32(3):133-8. PubMed ID: 12605276
[TBL] [Abstract][Full Text] [Related]
16. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
17. 11C-choline PET for the detection of bone and soft tissue tumours in comparison with FDG PET.
Zhang H; Tian M; Oriuchi N; Higuchi T; Watanabe H; Aoki J; Tanada S; Endo K
Nucl Med Commun; 2003 Mar; 24(3):273-9. PubMed ID: 12612468
[TBL] [Abstract][Full Text] [Related]
18. Use of FDG-PET in differentiating benign from malignant compression fractures.
Bredella MA; Essary B; Torriani M; Ouellette HA; Palmer WE
Skeletal Radiol; 2008 May; 37(5):405-13. PubMed ID: 18278491
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET in differential diagnosis and grading of chondrosarcomas.
Aoki J; Watanabe H; Shinozaki T; Tokunaga M; Inoue T; Endo K
J Comput Assist Tomogr; 1999; 23(4):603-8. PubMed ID: 10433294
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of hexokinase-2 in giant cell tumor of bone is associated with false positive in bone tumor on FDG-PET/CT.
Hoshi M; Takada J; Oebisu N; Hata K; Ieguchi M; Nakamura H
Arch Orthop Trauma Surg; 2012 Nov; 132(11):1561-8. PubMed ID: 22825642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]